Regional Lung Deposition and Clearance of 99mTc-Labeled Beclomethasone-DLPC Liposomes in Mild and Severe Asthma

Saari, Sina; Vidgrén, M.; Koskinen, Matti; Turjanmaa, Väinö; Waldrep, J. Clifford; Nieminen, Markku M.

doi:10.1378/chest.113.6.1573

Cited by 78 publications

(28 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liposomes have advantages over other potential vehicles for lung targeting including sustained release delivery of their cargo in the lungs, increased drug residence time in the lungs (McCullough and Juliano 1979, Morimoto and Adachi 1982, Taylor et al 1989, Couvreur et al 1991, Khanna et al 1996, Saari et al 1998, Bi and Zhang 2007, improved stability of the drug both in vitro and in vivo, improved biocompatibility (Niven and Schreier 1990), bioavailability (Huang and Wang 2006), local targeting providing increased potency and reduced toxicity (Wyde et al 1988, Gruber et al 1989, Clark et al 1991, Freise et al 1994, Khanna et al 1996, Griffiths et al 1999, Letsou et al 1999, Gavalda et al 2005a, 2005b. Also, the high loading capacity of liposomes and low excipient-to-drug ratio of lipid based carriers results in less excipient accumulation in the lungs after repeated administration compared to polymer-based carriers (Bhavane et al 2003).…”

Section: Introductionmentioning

confidence: 99%

Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation

Gibbons

McElvaney

Taggart

et al. 2009

Journal of Microencapsulation

View full text Add to dashboard Cite

Secretory leukocyte protease inhibitor (SLPI) is an endogenous serine protease inhibitor that protects the lungs from excessive tissue damage caused by leukocyte proteases released during inflammation. Recombinant SLPI (rSLPI) has shown potential as a treatment for inflammatory lung conditions. To date, its clinical application has been limited by rapid enzymatic cleavage by cathepsins and rapid clearance from the lungs after inhalation. In this study, rSLPI was encapsulated in 1,2-Dioleoylsn-Glycero-3-[Phospho-L-Serine] : Cholesterol (DOPS : Chol) liposomes for inhalation. Incubation of rSLPI with cathepsin L leads to complete loss of activity while encapsulation of rSLPI in DOPS : Chol liposomes retained 92.6% of its activity after challenge with cathepsin L. rSLPI-loaded liposomes were aerosolized efficiently using a standard nebulizer with a minimal loss of activity and stability. This formulation was biocompatible and encapsulation did not appear to diminish access to intracellular sites of action in in vitro cell culture studies. Liposome encapsulation of rSLPI therefore improves stability and potentially reduces the level and frequency of dosing required for therapeutic effect after inhalation.

show abstract

Section: Introductionmentioning

confidence: 99%

Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation

Gibbons

McElvaney

Taggart

et al. 2009

Journal of Microencapsulation

View full text Add to dashboard Cite

show abstract

“…Firstly, the reconstructed liposomes were labelled with 99mTc as described by Richardson et al [65]. Then, the pulmonary delivery and clearance of 99mTc-labelled beclomethasone dipropionate were analogized in 11 fit volunteers [66]. Both liposome aerosols have pertinent droplet size (diameter 1.3 mm) that are administered by Aerotech jet nebulizer and intend reflective pulmonary deposition.…”

Section: Comparison Of the Intrapulmonary Distribution And Clearance mentioning

confidence: 99%

Liposome as nanocarrier: Site targeted delivery in lung cancer

Ullah¹,

Noreen²,

Tehreem³

et al. 2017

APJTD

View full text Add to dashboard Cite

“…Human studies of liposome aerosols have demonstrated similar retention within the normal lung, but, depending on the presence of infl ammation (Vidgren et al 1994;Saari et al 1998). Factors affecting the clearance and/or elimination of exogenous materials from normal and diseased lung tissues are not yet completely understood.…”

Section: Liposomesmentioning

confidence: 99%

Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases

Vandamme¹

2008

IJN

View full text Add to dashboard Cite

Abstract:The purpose of this review is to discuss the impact of nanocarriers administered by pulmonary route to treat and to diagnose respiratory and non respiratory diseases. Indeed, during the past 10 years, the removal of chlorofl uorocarbon propellants from industrial and household products intended for the pulmonary route has lead to the developments of new alternative products. Amongst these ones, on one hand, a lot of attention has been focused to improve the bioavailability of marketed drugs intended for respiratory diseases and to develop new concepts for pulmonary administration of drugs and, on the other hand, to use the pulmonary route to administer drugs for systemic diseases. This has led to some marketed products through the last decade. Although the introduction of nanotechnology permitted to step over numerous problems and to improve the bioavailability of drugs, there are, however, unresolved delivery problems to be still addressed. These scientifi c and industrial innovations and challenges are discussed along this review together with an analysis of the current situation concerning the industrial developments.

show abstract

Regional Lung Deposition and Clearance of 99mTc-Labeled Beclomethasone-DLPC Liposomes in Mild and Severe Asthma

Cited by 78 publications

References 20 publications

Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation

Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation

Liposome as nanocarrier: Site targeted delivery in lung cancer

Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases

Contact Info

Product

Resources

About